Tian W, Niu L, Wang Z, Lu R, Xiao G, Deng F, Tanzhu G, Zhou R#. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States. Front Immunol. 2023 Sep 26;14:1268070. doi: 10.3389/fimmu.2023.1268070. PMID: 37822936 (JCR1区 IF=8.79)
发布时间：2026-10-01
点击次数：
是否译文：否
上一条： Mohammed N, Xiao EH, Mohsen S, Xiong Z, Zhou R#. PD-1/PD-L1 inhibitor treatment and its impact on clinical imaging in non-small cell lung cancer: a systematic review and meta-analysis of immune-related adverse events. Front Oncol. 2023 Sep 29;13:1191681. doi: 10.3389/fonc.2023.1191681. PMID: 37841435; PMCID: PMC10571717. (JCR2区 IF=6.24)
下一条： Deng F, Liu Z, Fang W, Niu L, Chu X, Cheng Q, Zhang Z, Zhou R#, Yang G. MRI radiomics for brain metastasis sub-pathology classification from non-small cell lung cancer: a machine learning, multicenter study. Phys Eng Sci Med. 2023 Sep;46(3):1309-1320. doi: 10.1007/s13246-023-01300-0. Epub 2023 Jul 17. PMID: 37460894 (JCR1区 IF=7.10)